GI Alliance - Fort Worth

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Crohn's disease2 trials
• Ulcerative colitis2 trials
• Fatty liver disease (MASLD/MASH)1 trial

Phase

• Phase 23 trials
• Phase 32 trials

Status

• Recruiting5 trials

Lead sponsor

• Eli Lilly and Company3 trials
• Agomab Spain S.L.U.1 trial
• Hoffmann-La Roche1 trial

Running trials

• Recruiting

  NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease

  NCT07683325· Phase 2· Agomab Spain S.L.U.· Source

  Contact: Agomab Clinical Operations

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

  Contact: Kumar Gutta (principal investigator)

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

  Contact: Kumar Gutta (principal investigator)

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Kumar Gutta (principal investigator)

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Ulcerative colitis2 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting